Literature DB >> 27959677

Biologic and Clinical Perspectives on Thyroid Cancer.

James A Fagin1, Samuel A Wells2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27959677     DOI: 10.1056/NEJMc1613118

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  36 in total

1.  Prognosis of FTC compared to PTC and FVPTC: findings based on SEER database using propensity score matching analysis.

Authors:  Zeming Liu; Wen Zeng; Lei Huang; Zhaoyuan Wang; Min Wang; Ling Zhou; Danyang Chen; Haifeng Feng; Wei Zhou; Liang Guo
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

2.  Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors:  R Michael Tuttle; Ali S Alzahrani
Journal:  J Clin Endocrinol Metab       Date:  2019-03-15       Impact factor: 5.958

Review 3.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

Review 4.  The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.

Authors:  Valentina De Falco; Francesca Carlomagno; Hong-Yu Li; Massimo Santoro
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2017-05-10       Impact factor: 4.690

5.  Thyroid Cancer: Is It All in the Genes?

Authors:  Electron Kebebew
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

6.  Pulmonary Function in Patients With Multiple Endocrine Neoplasia 2B.

Authors:  Sarah Fuller; Jaydira Del Rivero; David Venzon; Maran Ilanchezhian; Deborah Allen; Les Folio; Alexander Ling; Brigitte Widemann; Joseph R Fontana; John Glod
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

7.  Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.

Authors:  Vera Wenter; Annamirl Jellinek; Marcus Unterrainer; Freba Ahmaddy; Sebastian Lehner; Nathalie Lisa Albert; Peter Bartenstein; Thomas Knösel; Christine Spitzweg; Harun Ilhan; Andrei Todica
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

8.  MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.

Authors:  Julia Ramírez-Moya; León Wert-Lamas; Pilar Santisteban
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

9.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.

Authors:  Jeffrey A Knauf; Kathleen A Luckett; Kuen-Yuan Chen; Francesca Voza; Nicholas D Socci; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

10.  The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma.

Authors:  Yanqiang Wang; Huiling He; Sandya Liyanarachchi; Luke K Genutis; Wei Li; Lianbo Yu; John E Phay; Rulong Shen; Pamela Brock; Albert de la Chapelle
Journal:  Genet Med       Date:  2018-01-04       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.